These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12742490)

  • 21. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation.
    MacDonald AS
    Transplant Proc; 2003 May; 35(3 Suppl):201S-208S. PubMed ID: 12742497
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A microparticle enzyme immunoassay to measure sirolimus.
    Holt DW; Moreton M; Laamanen K; Johnston A
    Transplant Proc; 2005; 37(1):182-4. PubMed ID: 15808587
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sirolimus: the evidence for clinical pharmacokinetic monitoring.
    Stenton SB; Partovi N; Ensom MH
    Clin Pharmacokinet; 2005; 44(8):769-86. PubMed ID: 16029064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience.
    Wiseman AC; Kam I; Christians U; Jani A; Bak T; Wachs M; Chan L
    Transplant Proc; 2003 May; 35(3 Suppl):122S-124S. PubMed ID: 12742482
    [No Abstract]   [Full Text] [Related]  

  • 25. Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients.
    Chueh SC; Wang SM; Lai MK; Chen J
    Transplant Proc; 2004 Sep; 36(7):2058-9. PubMed ID: 15518745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus.
    Kovarik JM; Curtis JJ; Hricik DE; Pescovitz MD; Scantlebury V; Vasquez A
    Transplant Proc; 2006 Dec; 38(10):3456-8. PubMed ID: 17175302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining the initial doses of sirolimus and tacrolimus in the period immediately after renal transplantation.
    Jiménez O; Campistol JM; Vidal E; Faura A; Oppenheimer F; Corbella J; Brunet M
    Transplant Proc; 2003 Aug; 35(5):1686-8. PubMed ID: 12962758
    [No Abstract]   [Full Text] [Related]  

  • 28. Sirolimus: a current perspective.
    Yakupoglu YK; Kahan BD
    Exp Clin Transplant; 2003 Jun; 1(1):8-18. PubMed ID: 15859902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of pharmacogenetics of immunosuppressive drugs in organ transplantation.
    Thervet E; Anglicheau D; Legendre C; Beaune P
    Ther Drug Monit; 2008 Apr; 30(2):143-50. PubMed ID: 18367973
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of therapeutic drug monitoring of rapamycin.
    Kahan BD; Napoli KL
    Transplant Proc; 1998 Aug; 30(5):2189-91. PubMed ID: 9723436
    [No Abstract]   [Full Text] [Related]  

  • 31. Developmental pharmacogenetics of immunosuppressants in pediatric organ transplantation.
    Zhao W; Fakhoury M; Jacqz-Aigrain E
    Ther Drug Monit; 2010 Dec; 32(6):688-99. PubMed ID: 21068645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus: continuing the evolution of transplant immunosuppression.
    Ingle GR; Sievers TM; Holt CD
    Ann Pharmacother; 2000 Sep; 34(9):1044-55. PubMed ID: 10981252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
    Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J
    Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505
    [No Abstract]   [Full Text] [Related]  

  • 34. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 35. Pregnancy under sirolimus-based immunosuppression.
    Guardia O; Rial Mdel C; Casadei D
    Transplantation; 2006 Feb; 81(4):636. PubMed ID: 16495817
    [No Abstract]   [Full Text] [Related]  

  • 36. High-performance liquid chromatography versus immunoassay for the measurement of sirolimus: comparison of two methods.
    Zochowska D; Bartłomiejczyk I; Kamińska A; Senatorski G; Paczek L
    Transplant Proc; 2006; 38(1):78-80. PubMed ID: 16504669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation.
    Formica RN; Lorber KM; Friedman AL; Bia MJ; Lakkis F; Smith JD; Lorber MI
    Transplant Proc; 2003 May; 35(3 Suppl):95S-98S. PubMed ID: 12742475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacodynamic monitoring of mammalian target of rapamycin inhibition by phosphoflow cytometric determination of p70S6 kinase activity.
    Hoerning A; Wilde B; Wang J; Tebbe B; Jing L; Wang X; Jian F; Zhu J; Dolff S; Kribben A; Hoyer PF; Witzke O
    Transplantation; 2015 Jan; 99(1):210-9. PubMed ID: 25099702
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic monitoring of calcineurin inhibitors for the nephrologist.
    Schiff J; Cole E; Cantarovich M
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):374-84. PubMed ID: 17699437
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two rapid ultra performance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) methods with common sample pretreatment for therapeutic drug monitoring of immunosuppressants compared to immunoassay.
    Tszyrsznic W; Borowiec A; Pawlowska E; Jazwiec R; Zochowska D; Bartlomiejczyk I; Zegarska J; Paczek L; Dadlez M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jun; 928():9-15. PubMed ID: 23584041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.